# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-17-012106
Filing Date
2017-11-14
Accepted
2017-11-14 16:40:40
Documents
4
Period of Report
2017-12-20
Effectiveness Date
2017-11-14

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | def14a1217_actiniumpharma.htm | DEF 14A | 843350
2 | GRAPHIC | image001.jpg | GRAPHIC | 28604
3 | GRAPHIC | image002.jpg | GRAPHIC | 299368
4 | GRAPHIC | image003.jpg | GRAPHIC | 280372
| Complete submission text file | 0001213900-17-012106.txt |  | 1662374

Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 171202256
SIC: 2834 Pharmaceutical Preparations